In NAFLD/NASH clinical trials, liver biopsy is mandatory to assess eligibility and primary endpoints. It requires a lot of knowledge and skills to stage fibrosis and grade activity. Prof. Frank Bedossa discusses these important topics, as well as the different scores such as the NAFLD activity score (NAS) and the Steatosis Activity Fibrosis score (SAF).

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In